User profiles for Philip Ambery
 | Phil AmberyGlobal Clinical Head Verified email at astrazeneca.com Cited by 2565 |
[HTML][HTML] Intramuscular AZD7442 (tixagevimab–cilgavimab) for prevention of Covid-19
…, A Ellery, DJ Levinson, P Ambery… - … England Journal of …, 2022 - Mass Medical Soc
Background The monoclonal-antibody combination AZD7442 is composed of tixagevimab
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …
and cilgavimab, two neutralizing antibodies against severe acute respiratory syndrome …
[HTML][HTML] Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 …
…, J Buenconsejo, AM Langkilde, P Ambery… - The lancet Diabetes & …, 2021 - thelancet.com
Background COVID-19 can lead to multiorgan failure. Dapagliflozin, a SGLT2 inhibitor, has
significant protective benefits for the heart and kidney. We aimed to see whether this agent …
significant protective benefits for the heart and kidney. We aimed to see whether this agent …
Effects of cotadutide on metabolic and hepatic parameters in adults with overweight or obesity and type 2 diabetes: a 54-week randomized phase 2b study
OBJECTIVE Cotadutide, a dual GLP-1 and glucagon receptor agonist, is under development
for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes. …
for nonalcoholic steatohepatitis (NASH) and chronic kidney disease with type 2 diabetes. …
MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending …
P Ambery, VE Parker, M Stumvoll, MG Posch, T Heise… - The Lancet, 2018 - thelancet.com
Background Weight loss is often key in the management of obese or overweight patients with
type 2 diabetes, yet few treatments for diabetes achieve clinically meaningful weight loss. …
type 2 diabetes, yet few treatments for diabetes achieve clinically meaningful weight loss. …
Efficacy and safety of cotadutide, a dual glucagon‐like peptide‐1 and glucagon receptor agonist, in a randomized phase 2a study of patients with type 2 diabetes and …
…, M Petrone, L Hansen, P Ambery… - Diabetes, Obesity …, 2022 - Wiley Online Library
Aim To assess the efficacy, safety and tolerability of cotadutide in patients with type 2
diabetes mellitus and chronic kidney disease. Materials and Methods In this phase 2a study (…
diabetes mellitus and chronic kidney disease. Materials and Methods In this phase 2a study (…
Follicular helper T cell profiles predict response to costimulation blockade in type 1 diabetes
Follicular helper T (T FH ) cells are implicated in type 1 diabetes (T1D), and their development
has been linked to CD28 costimulation. We tested whether T FH cells were decreased by …
has been linked to CD28 costimulation. We tested whether T FH cells were decreased by …
Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID‐19: Design and rationale for the …
…, V Chopra, A Javaheri, P Ambery… - Diabetes, Obesity …, 2021 - Wiley Online Library
Aims Coronavirus disease 2019 (COVID‐19) is caused by a novel severe acute respiratory
syndrome coronavirus 2. It can lead to multiorgan failure, including respiratory and …
syndrome coronavirus 2. It can lead to multiorgan failure, including respiratory and …
Efficacy, safety, and mechanistic insights of cotadutide, a dual receptor glucagon-like peptide-1 and glucagon agonist
Context Cotadutide is a dual receptor agonist with balanced glucagon-like peptide-1 and
glucagon activity. Objective To evaluate different doses of cotadutide and investigate …
glucagon activity. Objective To evaluate different doses of cotadutide and investigate …
Cardiovascular safety of albiglutide in the Harmony programme: a meta-analysis
Background Albiglutide is a glucagon-like peptide-1 receptor agonist, a new class of drugs
used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety …
used to treat type 2 diabetes. We did a prospective meta-analysis of the cardiovascular safety …
MEDI0382, a GLP‐1/glucagon receptor dual agonist, meets safety and tolerability endpoints in a single‐dose, healthy‐subject, randomized, phase 1 study
Aims MEDI0382 is a balanced glucagon‐like peptide‐1/glucagon receptor dual agonist
under development for the treatment of type 2 diabetes mellitus and non‐alcoholic …
under development for the treatment of type 2 diabetes mellitus and non‐alcoholic …
